After coating with H22‐specific neoantigen activated DC membrane, it not only enables to actively target to tumors for efficient PDT to enhance ICDs for in situ vaccination to strengthen TAA related T‐cell response, but also possess an excellent lymph‐homing effect to directly induce the activation and proliferation of TSA‐specific CD8+T cell immunity to suppress both the primary tumor and distal tumor growth. The gene discussed is CD8A; the disease is neoplasm.